Adell Harriman & Carpenter Boosted Its Jazz Pharmaceutical Splc (JAZZ) Position; 4 Analysts Covering Fang Holdings Ltd (SFUN)

November 17, 2017 - By Dolores Ford

Among 12 analysts covering SouFun Holdings (NYSE:SFUN), 4 have Buy rating, 3 Sell and 5 Hold. Therefore 33% are positive. SouFun Holdings had 20 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, August 10 by Nomura. Morgan Stanley upgraded Fang Holdings Ltd (NYSE:SFUN) rating on Monday, March 21. Morgan Stanley has “Overweight” rating and $7 target. The firm has “Hold” rating by Brean Capital given on Tuesday, June 7. Benchmark maintained the stock with “Hold” rating in Wednesday, April 19 report. The rating was downgraded by CLSA on Monday, August 10 to “Buy”. Nomura downgraded the stock to “Reduce” rating in Tuesday, November 29 report. Goldman Sachs downgraded it to “Neutral” rating and $7.70 target in Monday, November 30 report. The stock of Fang Holdings Ltd (NYSE:SFUN) earned “Neutral” rating by JP Morgan on Wednesday, August 31. CLSA downgraded the stock to “Sell” rating in Friday, August 26 report. Deutsche Bank downgraded the shares of SFUN in report on Wednesday, December 14 to “Sell” rating. See Fang Holdings Ltd (NYSE:SFUN) latest ratings:

16/06/2017 Broker: TH Capital Rating: Buy Old Target: $9.00 New Target: $4.50 Target Down

Adell Harriman & Carpenter Inc increased Jazz Pharmaceutical Splc (JAZZ) stake by 57.73% reported in 2017Q2 SEC filing. Adell Harriman & Carpenter Inc acquired 6,200 shares as Jazz Pharmaceutical Splc (JAZZ)’s stock rose 8.72%. The Adell Harriman & Carpenter Inc holds 16,940 shares with $2.63B value, up from 10,740 last quarter. Jazz Pharmaceutical Splc now has $8.01B valuation. It closed at $133.53 lastly. It is down 1.25% since November 17, 2016 and is uptrending. It has underperformed by 15.45% the S&P500.

Adell Harriman & Carpenter Inc decreased Chevrontexaco (NYSE:CVX) stake by 3,735 shares to 25,236 valued at $2.63 billion in 2017Q2. It also reduced Procter&Gamble (NYSE:PG) stake by 3,110 shares and now owns 52,770 shares. Johnsn&Johnsn (NYSE:JNJ) was reduced too.

Investors sentiment increased to 1.39 in 2017 Q2. Its up 0.44, from 0.95 in 2017Q1. It improved, as 31 investors sold JAZZ shares while 79 reduced holdings. 51 funds opened positions while 102 raised stakes. 51.74 million shares or 0.45% less from 51.98 million shares in 2017Q1 were reported. Pioneer Inv Mngmt accumulated 836,427 shares or 0.43% of the stock. Virginia Retirement Et Al holds 13,300 shares or 0.03% of its portfolio. Rdl Fincl has invested 1.96% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Price T Rowe Associate Inc Md owns 194,033 shares for 0.01% of their portfolio. Eaton Vance Mngmt invested in 0.05% or 122,771 shares. Moreover, Sg Americas Secs Ltd has 0% invested in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). 30,308 were reported by Gotham Asset Mgmt Ltd Limited Liability Company. Prelude Cap Mgmt Limited Co invested in 0.25% or 16,759 shares. Westfield Capital Co Lp reported 1.32 million shares. Neuberger Berman Group Incorporated Ltd Llc invested 0.02% of its portfolio in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Aviva Public Limited Com reported 0.03% stake. Condor Capital Mgmt invested in 0.28% or 8,498 shares. Gargoyle Inv Advisor Limited Liability Company invested 0.08% of its portfolio in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Lincoln Natl holds 0.02% of its portfolio in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) for 2,272 shares. Wells Fargo Mn has invested 0.02% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ).

Since June 1, 2017, it had 0 insider purchases, and 2 insider sales for $780,130 activity. MILLER MICHAEL PATRICK sold $30,130 worth of stock. On Thursday, June 1 the insider Winningham Rick E sold $750,000.

Among 21 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 16 have Buy rating, 0 Sell and 5 Hold. Therefore 76% are positive. Jazz Pharmaceuticals had 63 analyst reports since August 3, 2015 according to SRatingsIntel. As per Tuesday, June 27, the company rating was maintained by Cantor Fitzgerald. The firm has “Buy” rating by Deutsche Bank given on Wednesday, August 9. The company was maintained on Friday, July 14 by Piper Jaffray. The firm has “Buy” rating by FBR Capital given on Wednesday, October 18. The firm earned “Buy” rating on Friday, October 20 by Piper Jaffray. Mizuho maintained Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) on Wednesday, May 31 with “Hold” rating. SunTrust upgraded the stock to “Buy” rating in Monday, April 25 report. The firm has “Outperform” rating given on Friday, February 19 by Wells Fargo. The firm has “Buy” rating given on Wednesday, May 11 by Mizuho. The rating was maintained by Piper Jaffray with “Buy” on Thursday, September 14.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.